Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03830320 · ClinicalTrials.gov registry record · Phase 1

Positron Emission Tomography (PET) Imaging of Thrombosis

A Phase 1 study of Cancer and Atrial Fibrillation, sponsored by Massachusetts General Hospital.

Recruiting
Registry status
Phase 1
Development phase
165
Enrollment target
1
Study location

NCT03830320 is a Phase 1 study of Cancer and Atrial Fibrillation that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 165 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03830320, a Phase 1 study of Cancer and Atrial Fibrillation, is actively recruiting participants, sponsored by Massachusetts General Hospital.

RECRUITING
Registry status
Phase 1
Development phase
165 participants
Enrollment target
1
Study location

Study Summary

The purpose of the study is to evaluate a new radiotracer called 64Cu-FBP8 for PET-MR imaging of thrombosis. The tracer has the potential of detecting thrombosis anywhere in the body, for instance in the left atrial appendage of patients with atrial fibrillation, and thereby may provide a non-invasive alternative to the current standard-of-care methods.

Interventions

  • PROCEDURE Electrocardiogram
  • DRUG [64Cu]FBP8
  • DEVICE PET/MR
  • PROCEDURE Blood Collection

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 165 participants
Start Date 2016-04-01
Est. Completion 2027-01-31
Phase Phase 1

Sponsor

Massachusetts General Hospital

2,032 total trials

What the Registry Record Tells You About NCT03830320

The ClinicalTrials.gov registry entry for NCT03830320 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 165 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (95% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Cancer appearing as the primary indexed condition, and to 4 interventions - of which Electrocardiogram is the first listed.

NCT03830320 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT03830320 about?

NCT03830320 is a clinical study titled "Positron Emission Tomography (PET) Imaging of Thrombosis". The purpose of the study is to evaluate a new radiotracer called 64Cu-FBP8 for PET-MR imaging of thrombosis. The tracer has the potential of detecting thrombosis anywhere in the body, for instance in the left atrial appendage of patients with atrial fibrillation, and thereby may provide a non-invasi...

What is the current status of trial NCT03830320?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 165 participants. The study started on 2016-04-01. Estimated completion is 2027-01-31.

What conditions does trial NCT03830320 study?

This clinical trial studies the following conditions: Cancer, Atrial Fibrillation, COVID-19, Thrombosis.

What interventions are being tested in trial NCT03830320?

The interventions under investigation include: Electrocardiogram (PROCEDURE), [64Cu]FBP8 (DRUG), PET/MR (DEVICE), Blood Collection (PROCEDURE).

Who is sponsoring clinical trial NCT03830320?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03830320 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.